Axsome Therapeutics Launches Phase 3 Trial for Smoking Cessation Drug AXS-05 — Axsome Therapeutics, Inc.

Event summary

Axsome Therapeutics initiated the SUMMIT Phase 3 trial for AXS-05 in smoking cessation on August 31, 2026.
The trial is a randomized, double-blind, active- and placebo-controlled study with a primary endpoint of smoking abstinence at 12 weeks.
AXS-05 is a novel, oral, investigational drug covered by patents extending to at least 2043.
The drug is already approved for major depressive disorder and agitation associated with Alzheimer’s disease.

The big picture

Axsome Therapeutics is expanding its portfolio beyond approved indications for major depressive disorder and Alzheimer’s-related agitation, targeting the substantial market for smoking cessation. The SUMMIT trial represents a strategic pivot into a high-need area with limited effective treatments, potentially positioning AXS-05 as a differentiated therapy if successful. The company’s robust patent estate and existing regulatory experience could streamline its path to approval, but competition and reimbursement dynamics remain critical factors.

What we're watching

Clinical Trial Success: Whether AXS-05 demonstrates superior efficacy and safety compared to bupropion and placebo in achieving smoking abstinence.
Regulatory Pathway: The pace at which Axsome can secure FDA approval for AXS-05 in smoking cessation, given its existing approvals in other indications.
Market Potential: How AXS-05 could capture market share in the smoking cessation space, addressing a significant unmet need with over 34 million adult smokers in the U.S.